# Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

> **NCT02870348** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 4 (actual)

## Conditions studied

- Alpha1-Antitrypsin Deficiency

## Interventions

- **BIOLOGICAL:** Alpha-1 MP

## Key facts

- **NCT ID:** NCT02870348
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-29
- **Primary completion:** 2021-02-16
- **Final completion:** 2021-02-16
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02870348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02870348, "Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02870348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*